Australian biotech market today 13.03.09
Friday, 13 March, 2009
Biotech and pharma stocks were up 1.5 per cent on trading at 2pm compared to a rise in the All Ordinaries of three per cent, on a good day for the Australian sharemarket overall.
Alchemia (ASX:ACL) is up 5c on news that its manufacturing partner Dr Reddy’s Laboratories had filed a new drug application with the US FDA for a generic version of fondaparinux, an anti-coagulant used for treating blood clots.
pSivida (ASX:PVA) was up eight per cent to $1 following its report of good interim results in a Phase II trial of an intra-vitreal insert for diabetic macular oedema.
CSL (ASX:CSL) is up 40c but is still down on its year high of $38.50, while Sonic Healthcare recovered 40c on yesterday’s year low of $9.96.
Acrux (ASX:ACR) and Cellestis (ASX:CST) were up slightly on very small volumes.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
